Publications, Research & Innovation

Dr  Sean  Hall, MD, PhD, MBA, is a published clinical researcher and inventor whose work informs policy‑relevant decision‑making at the intersection of healthcare innovation, regulation, and system sustainability. His peer‑reviewed research spans clinical medicine, microbiome science, immunology, cannabinoid therapeutics, and translational healthcare innovation, with particular relevance to chronic disease and oncology‑related co‑morbidities.

A key focus of Dr Hall’s work has been the development and translation of novel therapeutic delivery systems, including advanced nanoparticle and oro‑buccal platforms designed to improve bioavailability, dosing consistency, and patient adherence. These innovations support more effective management of complex conditions such as cancer‑associated pain, inflammation, and mental health burden, complementing primary clinical care.

Dr Hall is the inventor and international patent holder of multiple healthcare technologies, reflecting practical expertise in aligning scientific innovation with regulatory requirements and real‑world implementation. His research and intellectual property activities underpin evidence‑based advisory work for governments, regulators, and healthcare organisations evaluating innovation adoption, translational readiness, and long‑term system impact.

Professional & Research Profiles

Research Impact Summary

Dr Sean Hall, MD, PhD, MBA brings a research‑impact profile grounded in the translation of clinical science into regulated, scalable healthcare solutions with measurable system‑level relevance. His work informs board‑ and policy‑level decision‑making across healthcare innovation, life sciences strategy, and health‑system sustainability, particularly in areas characterised by high prevalence, cost burden, and clinical complexity.

In the United States, chronic and co‑morbid conditions account for approximately 90% of national healthcare expenditure, with an estimated 6 in 10 adults living with at least one chronic disease and associated long‑term care needs. Chronic pain alone affects more than 50 million U.S. adults, with total annual economic costs—combining healthcare utilisation, lost productivity, and disability—estimated between $560–$635 billion, exceeding the costs of heart disease, cancer, and diabetes individually. [cdc.gov], [nihcm.org][cdc.gov], [ncbi.nlm.nih.gov], [practicalb...ethics.org]

Within oncology, research demonstrates that approximately 55% of U.S. adults living with cancer report clinically significant pain, with associated healthcare expenditures averaging $4,000–$5,000 higher per patient per year compared to those without pain, driven by inpatient, outpatient, and pharmaceutical utilisation. National cancer care costs are projected to exceed $240 billion annually by 2030, with survivorship and co‑morbid condition management accounting for a substantial and growing share of expenditure. [pmc.ncbi.nlm.nih.gov], [valueinhea...ournal.com][costprojec...cancer.gov], [cdc.gov]

Dr Hall’s research has focused on addressing these pressures through advanced therapeutic delivery systems, including nanoparticle and oro‑buccal platforms designed to improve bioavailability, dosing consistency, and patient adherence. Such innovations have direct relevance to managing cancer‑related co‑morbidities—such as pain, inflammation, metabolic disruption, and neuro‑psychological burden—where improved delivery efficiency can reduce variability, optimise outcomes, and support more efficient use of existing therapies.

As an inventor and international patent holder, Dr Hall has generated intellectual property portfolios that bridge discovery science and real‑world implementation. His patent generation and translational leadership reflect practical expertise in aligning innovation with regulatory standards, manufacturability, and adoption pathways—an essential consideration for governments and boards assessing return on research investment and long‑term system value.

Collectively, Dr Hall’s research and innovation activities provide evidence‑based insight into how healthcare innovation can be responsibly integrated into existing systems to address high‑prevalence, high‑cost conditions while maintaining safety, effectiveness, and economic sustainability.